Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Level 3 Communications, Inc. (NYSE: LVLT) shares increased 6.17 percent to close at $26.00 a share Wednesday. The stock traded between $24.49 and $26.17 on volume of 4.86 million shares traded. The company announced that it has expanded its Vyvx broadcast capabilities into South Africa to meet growing demand. Shares of Level 3 Communications have gained approximately 12.5 percent year-to-date.
Get more information on Level 3 Communications and free access to the in-depth equity report at:
www.FiveStarEquities.com/LVLT
RTI Surgical Inc. (NASDAQ: RTIX) shares surged 11.97 percent to close at $3.93 a share Wednesday. The stock traded between $3.56 and $4.01 on volume of 669,418 shares traded. The company announced the successful completion of a FDA inspection of its Alachua, Fla. Facility. Shares of RTI Surgical have fallen approximately 8.0 percent year-to-date.
Get more information on RTI Surgical and free access to the in-depth equity report at:
www.FiveStarEquities.com/RTIX
Take-Two Interactive Software, Inc. (NASDAQ: TTWO) shares declined 4.63 percent to close at $17.30 a share Wednesday. The stock traded between $16.96 and $17.98 on volume of 7.01 million shares traded. Despite the upcoming release of the much anticipated "Grand Theft Auto V", Pacific Crest analyst Evan Wilson has downgraded the company’s rating to "sector perform" from "outperform". Shares of Take-Two Interactive have gained approximately 57.0 percent year-to-date.
Get more information on Take-Two Interactive and free access to the in-depth equity report at:
www.FiveStarEquities.com/TTWO
Ventrus Biosciences Inc. (NASDAQ: VTUS) shares surged 15.12 percent to close at $2.97 a share Wednesday. The stock traded between $2.82 and $3.75 on volume of 7.88 million shares traded. The company reported positive results from a clinical trial of Diltiazem, a treatment for anal fissures. Shares of Ventrus Biosciences have gained approximately 37.0 percent year-to-date.
Get more information on Ventrus Biosciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/VTUS
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com